SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 92 filers reported holding SPERO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $151,250 | -16.6% | 125,000 | 0.0% | 0.05% | -6.0% |
| Q2 2023 | $181,250 | 0.0% | 125,000 | 0.0% | 0.05% | -7.4% |
| Q1 2023 | $181,250 | -16.2% | 125,000 | 0.0% | 0.05% | -11.5% |
| Q4 2022 | $216,250 | -13.5% | 125,000 | 0.0% | 0.06% | -9.0% |
| Q3 2022 | $250,000 | -77.6% | 125,000 | +25.0% | 0.07% | -81.5% |
| Q3 2020 | $1,116,000 | +186.9% | 100,000 | +107.9% | 0.36% | +124.1% |
| Q1 2020 | $389,000 | -6.9% | 48,103 | +22.1% | 0.16% | +3.2% |
| Q3 2019 | $418,000 | -48.1% | 39,395 | -43.7% | 0.16% | -48.2% |
| Q2 2019 | $806,000 | -10.1% | 70,000 | 0.0% | 0.30% | -21.7% |
| Q1 2019 | $897,000 | +108.1% | 70,000 | 0.0% | 0.39% | +80.8% |
| Q4 2018 | $431,000 | -41.4% | 70,000 | 0.0% | 0.21% | -29.1% |
| Q3 2018 | $736,000 | +74.8% | 70,000 | +136.9% | 0.30% | +47.3% |
| Q1 2018 | $421,000 | +613.6% | 29,544 | +490.9% | 0.20% | +540.6% |
| Q4 2017 | $59,000 | – | 5,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 3,932,209 | $76,246,000 | 15.85% |
| Atlas Venture Associates XI, LLC | 1,376,968 | $26,700,000 | 4.23% |
| Atlas Venture Associates IX, LLC | 1,376,968 | $26,700,000 | 4.23% |
| BVF INC/IL | 2,243,278 | $43,497,000 | 1.71% |
| AWM Investment Company, Inc. | 372,755 | $7,228,000 | 0.92% |
| Alphabet Inc. | 889,979 | $17,257,000 | 0.83% |
| Rock Springs Capital Management LP | 1,235,000 | $23,947,000 | 0.51% |
| Novo Holdings A/S | 576,702 | $11,182,000 | 0.48% |
| Artal Group S.A. | 500,000 | $9,695,000 | 0.21% |
| Granahan Investment Management | 420,320 | $8,150,000 | 0.18% |